A double-blind, parallel-group, single-dose, bioequivalence study of CHS-1420 compared with Humira in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational
- 15 Dec 2014 Status changed from recruiting to completed, according to Coherus BioSciences SEC filing report 10-Q 2014.
- 19 Aug 2014 New trial record
- 14 Aug 2014 Primary endpoint "area under the time-concentration curve: AUC0-t and AUC0-inf" has been met, according to a Coherus BioSciences media release.